US EditionHealth Canada approves Ozempic to reduce kidney deterioration in people with diabetes
Health Canada approved Ozempic after a trial showed a 24% lower risk of kidney deterioration and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease.
- On Aug. 13, Health Canada approved Ozempic to reduce eGFR decline, end-stage kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease.
- Last year, the peer-reviewed FLOW trial funded by Novo Nordisk was published in the New England Journal of Medicine, supporting Health Canada’s approval of Ozempic for kidney protection in people with Type 2 diabetes.
- Following long-term follow-up, researchers found Ozempic recipients had a 24 per cent lower risk of kidney deterioration or failure compared to placebo in the FLOW trial, which tracked 3,533 patients for 3.4 years.
- Experts at Toronto General Hospital and UBC emphasized the psychological relief of lowering patients’ fear of dialysis, with Dr. David Cherney saying results suggest possible kidney function preservation before dialysis or transplant, calling it 'potential to reduce kidney function loss.'
- By approving Ozempic for dual renal and cardiovascular protection, regulators signal a shift in diabetes care, supported by the FLOW trial which showed a 24 per cent lower risk of kidney deterioration.
34 Articles
34 Articles
Ozempic Approved in Canada to Reduce Kidney Decline in Type 2 Diabetes Patients
Canada has approved Ozempic to reduce the risk of further kidney decline in patients with Type 2 diabetes. Ozempic is the brand name of an injectable form of semaglutide, which is a glucagon-like peptide-1 hormone. It was first approved in Canada as a diabetes medication because it reduces blood sugar. It has previously been approved as a weight loss drug under the brand name Wegovy for people with obesity, as it can reduce appetite. Manufacture…
Health Canada approves Ozempic to reduce kidney deterioration in people with diabetes (Business)
Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes. Between 30 and 50 per cent of people with Type 2 diabetes develop some form of chronic kidney disease. An international clinical trial, called FLOW, showed the risk of kidneys signifi...
Coverage Details
Bias Distribution
- 62% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
